SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) announced that Gisela Schwab, M.D., the company’s executive vice president and chief medical officer, will present at the Leerink Swann Cancer Roundtable Conference at 1:55 p.m. EDT / 10:55 a.m. PDT on Thursday, April 7, 2011, in New York. During the presentation, Dr. Schwab will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer (CRPC), discuss the pivotal trial plans and regulatory strategy for the compound in CRPC and provide a general business update.
The presentation will be webcast and may be accessed in the Event Calendar under Investors at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company’s web site at www.exelixis.com.
CONTACT:
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Investor Relations and Corporate Communications
[email protected]
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Research FDA Science
MEDIA:
| Logo |